---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-087280"
form_type: "8-K"
ticker: "BNBX"
cik: "0000744452"
company_name: "BNB PLUS CORP."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:25:18.506739+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Applied DNA Sciences Q3 FY2024 revenue falls 72% YoY to $798K; operating loss widens

## Summary
- Total revenues $798K for Q3 ended June 30, 2024, down from $2.9M, driven by end of CUNY COVID testing contract.
- Gross profit $245K (31% margin) vs $1.3M (44%); operating loss $3.3M vs $2.9M year ago.
- Adjusted EBITDA negative $3.2M vs negative $2.1M; cash position $10.4M up from $7.2M after $10.5M public offering.
- LineaRx GMP facility on track for FY24 year-end launch; Linea IVT GMP runs expected early CY25.
- Multi-year certainT agreement with Indus Group post-close; TR8 PGx testing capacity set at potential $25M annual revenue.

## SEC filing metadata
- accession: 0001104659-24-087280
- form_type: 8-K
- ticker: BNBX
- cik: 0000744452
- company_name: BNB PLUS CORP.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744452/000110465924087280/0001104659-24-087280-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744452/000110465924087280/tm2421159d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-087280
- JSON: https://secwatch.observer/filing/0001104659-24-087280.json
- Plain text: https://secwatch.observer/filing/0001104659-24-087280.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.